Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia research"
DOI: 10.1016/j.leukres.2021.106610
Abstract: Gilteritinib is primarily metabolized via cytochrome P450 (CYP). Therefore, concomitant administration of strong CYP3A4 inducers or inhibitors is not recommended. We evaluated the incidence of gilteritinib-related adverse events (AEs) in 47 patients who received gilteritinib… read more here.
Keywords: fungal diseases; gilteritinib; prophylaxis treatment; gilteritinib triazole ... See more keywords